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E d i t o r i a l
Hyperphosphatemia is a common problem in patients
with end-stage renal disease. In this issue, Goodman (1)
gives an extensive review on the novel management
of renal bone disease, the result of secondary hyper-
parathryoidism, and associated hyperphosphatemia.
On the contrary, hypophosphatemia is not an uncommon
disorder in post-renal-transplant patients. More than 50%
of post-renal-transplant patients in a major renal unit in
Hong Kong have hypophosphatemia (2). Phosphate
supplements may be needed during the early post-
transplant period to correct hypophosphatemia (2).
The kidneys have an important role in the maintenance
of phosphate balance. About 80% to 85% of the
phosphate filtered at the glomeruli is reabsorbed.
Glomerular filtration rate (GFR) declines with renal
failure. With the initial fall in GFR, filtered phosphate
load as well as excretion are diminished. The net effect
will be phosphate retention and a small increase in the
plasma phosphate concentration. This small increase in
phosphate will combine with ionized calcium. The
lowered ionized calcium level stimulates secretion of
parathyroid hormone (PTH) and results in secondary
hyperparathyroidism, as proposed in the “trade-off”
hypothesis (3,4). However, the initial minor increase in
phosphate may not be sufficient to cause a significant
hypocalcemia to enhance hypersecretion of PTH (5).
Recent studies have demonstrated that phosphate may
directly enhance PTH secretion (6). In early chronic renal
failure, phosphate retention suppresses 1α-hydroxylase
activity, thus the renal synthesis of 1,25-dihydroxyvitamin
D3 that has inhibitory effect on the parathyroid gland.
Dietary phosphate restriction may restore vitamin D3
levels and diminish PTH secretion (7,8).
The initial hypersecretion of PTH is appropriate in the
sense that it inhibits phosphate reabsorption in proximal
tubules and lowers the plasma phosphate concentration
towards normal. However, in the long run, the hyper-
parathyroidism is maladaptive. Chronic exposure to high
levels of PTH can lead to potentially serious bone disease.
In addition, PTH fails to increase phosphate excretion
when GFR declines to less than 20 mL/min. At this point,
decreased phosphate excretion and increased phosphate
release from bone by PTH would result in persistent
hyperphosphatemia, if phosphate intake is not diminished.
A vicious cycle is developed as hyperphosphatemia
stimulates further PTH release directly (9).
Following successful renal transplantation, hypo-
phosphatemia may develop secondary to urinary
phosphate wasting. Although this complication may be
due to hyperparathyroidism-dependent or -independent
mechanisms (10), pretransplant serum phosphate level
is significantly higher in hypophosphatemic than the
normophosphatemic group (2). Oral phosphate supple-
mentation is the common treatment. Unfortunately,
administration of oral phosphate may exacerbate
hyperparathyroidism due to its complexion with calcium
and lowering intestinal calcium absorption.
To break the viscous cycle of hyperphosphatemia-
hyperparathyroidism, maintaining normal plasma
phosphate is the mainstay of therapy in chronic renal
failure. The review by Goodman (1) in this issue outlines
all the possible ways to control hyperphosphatemia. The
use of newer and potentially safer phosphate binder
(sevelamer), calcimimectic agents, as well as nocturnal
hemodialysis has been proposed and proven effective in
lowering hyperphosphatemia and thus hyperpara-
thyroidism. However, these treatments are associated
with increased cost and they are usually instituted after
hyperphosphatemia and secondary hyperparathyroidism
are established.
In advanced chronic renal failure with creatinine
clearance below 15 to 20 mL/min, patients are referred
to nephrologists. They are then started on a combination
of low protein, low phosphate diet and phosphate binders.
These measures may help to lower serum PTH levels,
but patients have to comply with a rather monotonous
diet. Milk, cheese, eggs, meat, fish, peas, beans, soya
products, and cereals have to be reduced or restricted.
Compliance to this diet is doubtful and benefit is
questionable at this stage.
Coburn et al (11) suggested that the optimal benefits of
preventing secondary hyperparathyroidism are best
achieved when creatinine clearance is still within the 25-
to-60 mL/min range. Lower phosphate level may also
slow down the progression of renal failure (12). Long-
term survivors with non-progressive chronic renal failure
have unusually low plasma phosphate. This supports the
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view that hyperphosphatemia has an independent
deleterious effect. To prevent the progression of renal
failure and its complications, more research on the effect
of phosphate on renal failure and PTH secretion should
be carried out at the early stage of renal failure when the
creatinine clearance is still above 50%.
Alex Wai-Yin Yu
Editor-in-Chief
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